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Abstract
Background: Some studies have shown that nasally administered immunobiotics had the potential to improve the
outcome of influenza virus infection. However, the capacity of immunobiotics to improve protection against
respiratory syncytial virus (RSV) infection was not investigated before.
Objective: The aims of this study were: a) to evaluate whether the nasal administration of Lactobacillus rhamnosus
CRL1505 (Lr05) and L. rhamnosus CRL1506 (Lr06) are able to improve respiratory antiviral defenses and beneficially
modulate the immune response triggered by TLR3/RIG-I activation; b) to investigate whether viability of Lr05 or
Lr06 is indispensable to modulate respiratory immunity and; c) to evaluate the capacity of Lr05 and Lr06 to improve
the resistance of infant mice against RSV infection.
Results: Nasally administered Lr05 and Lr06 differentially modulated the TLR3/RIG-I-triggered antiviral respiratory
immune response. Lr06 administration significantly modulated the production of IFN-α, IFN-β and IL-6 in the
response to poly(I:C) challenge, while nasal priming with Lr05 was more effective to improve levels of IFN-γ and
IL-10. Both viable Lr05 and Lr06 strains increased the resistance of infant mice to RSV infection while only heat-killed
Lr05 showed a protective effect similar to those observed with viable strains.
Conclusions: The present work demonstrated that nasal administration of immunobiotics is able to beneficially
modulate the immune response triggered by TLR3/RIG-I activation in the respiratory tract and to increase the resistance
of mice to the challenge with RSV. Comparative studies using two Lactobacillus rhamnosus strains of the same origin
and with similar technological properties showed that each strain has an specific immunoregulatory effect in the
respiratory tract and that they differentially modulate the immune response after poly(I:C) or RSV challenges, conferring
different degree of protection and using distinct immune mechanisms. We also demonstrated in this work that it is
possible to beneficially modulate the respiratory defenses against RSV by using heat-killed immunobiotics.
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Background
Acute lower respiratory tract infections are a persistent
public health problem. Despite the remarkable advances
in antibiotic therapies, diagnostic tools, prevention cam-
paigns and intensive care, respiratory infections are still
among the primary causes of death worldwide, and there
have been no significant changes in mortality in the last
decades [1]. Childhood acute community-acquired pneu-
monia is one of the leading causes of morbidity and
mortality in developing countries. In children who have
not received prior antibiotic therapy, the main bacterial
causes of clinical pneumonia in developing countries are
Streptococcus pneumoniae and Haemophilus influenzae
type b, and the main viral cause is the respiratory syncyt-
ial virus [2].
Respiratory syncytial virus (RSV), a pneumovirus in the
family Paramyxoviridae, infects nearly all children within
the first 3 years of life. Primary RSV infections can cause
severe bronchiolitis and pneumonia, which are associated
with significantly increased risk of developing wheeze dur-
ing childhood that lasts until teenage years. Symptomatic
reinfections occur in every age group, but the frequency
and severity of symptoms are highest in children below 5
years of age [3]. As described for several respiratory vi-
ruses, such as pandemic influenza virus strains and the
human coronavirus that causes SARS, it is believed that
the immune response plays a critical role in the outcome
of RSV-induced bronchiolitis and pneumonia. Acute RSV
infection is able to induce an exacerbated disease due to
immune-mediated pulmonary injury resulting in severe
morbidity and mortality [4]. Therefore, identifying novel
approaches to modulate virus-induced immunopathology
would be beneficial in treating acute RSV infections.
Several studies have demonstrated that certain lactic
acid bacteria (LAB) strains can exert their beneficial effect
on the host through their immunomudulatory activity. In
this regard, some studies have centered on whether immu-
noregulatory probiotic LAB (immunobiotics) might suffi-
ciently stimulate the common mucosal immune system to
provide protection in other mucosal sites distant from the
gut [5]. The studies of our laboratory demonstrated that
some orally administered LAB are able to increase S.
pneumoniae clearance rates in lung and blood, improve
survival of infected mice and reduce lung injuries [5-8].
Moreover, we found that the effects of LAB treatments
were related to an up-regulation of both respiratory innate
and adaptive immune responses. In addition, considering
that the nasal route can induce systemic and respiratory
immune responses superior to those obtained using oral
stimulation [9], we also focused on the ability of nasal
stimulation with immunobiotics to improve respiratory
immune responses. Our studies showed that nasally ad-
ministered LAB are capable of modulating lung immunity
and increase resistance against S. pneumoniae in both
immunocompetent and immunocompromised mice and
that in many cases, nasal priming is more effective than
oral administration to beneficially modulate the respira-
tory immunity [10,11].
Recently, our laboratory studied the capacity of
immunobiotics to improve respiratory antiviral im-
mune response. To mimic the pro-inflammatory and
physiopathological consequences of RNA viral infections
in the lung such as those induced by RSV infection, we
used an experimental model of lung inflammation based
on the administration of the artificial toll-like receptor 3
(TLR3) and retinoic acid–inducible gene I (RIG-I) ligand
and dsRNA analog poly(I:C) [12]. In vivo studies using
mice demonstrated that nasally administered poly(I:C) re-
sults in TLR3- and CXCR2-dependent neutrophilic pul-
monary inflammation, bronchiolar epithelial hypertrophy,
interstitial edema and altered lung function [13,14]. These
changes are accompanied by elevated levels of interleukin
(IL)-8, RANTES, monocyte chemotactic protein (MIP)-1,
and type I interferons (IFNs) in broncho-alveolar lavages
(BAL) [13]. When we evaluated the effect of two Lactoba-
cillus strains, Lactobacillus rhamnosus CRL1505 (Lr05)
and L. rhamnosus CRL1506 (Lr06) in this mice model, we
found that orally administered Lr05 beneficially regulate
the balance between pro-inflammatory mediators and
IL-10 in lung of poly(I:C)-challenged mice, allowing an
effective control of the inflammatory response and
avoiding tissue damage [12]. Moreover, our studies
demonstrated that Lr05 is able to increase the number
of CD3+CD4+IFN-γ+ T cells in the gut, induce the
mobilization of these cells into the respiratory mucosa
and improve the local production of IFN-γ and the ac-
tivity of lung antigen presenting cells (APCs) [12]. Our
results suggested that Lr05 is a potent inducer of anti-
viral cytokines and may be useful as a prophylactic
agent to control respiratory virus infections. However,
whether the nasal priming with Lr05 is more effective
than oral administration to beneficially modulate the
respiratory immune response triggered by poly(I:C)
challenge has not been evaluated before. Moreover, fur-
ther studies using real challenges with respiratory vi-
ruses such as RSV are needed in order to conclusively
demonstrate the protective effect of Lr05.
Considering this background, the aims of this study were:
a) to investigate whether the nasal administration of Lr05 or
Lr06 are able to improve respiratory antiviral defenses and
beneficially modulate the immune response triggered by
TLR3/RIG-I activation; b) to evaluate whether viability of
Lr05 or Lr05 is indispensable to modulate respiratory im-
munity considering that it was reported that heat-killed
lactobacilli strains are able to improve lung defenses
[11,15,16] and; c) to conclusively demonstrate the protective
effect of Lr05 and Lr06 by evaluating their capacity to im-
prove the resistance of infant mice against RSV challenge.
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Methods
Microorganisms
Lactobacillus rhamnosus CRL1505 (Lr05) and CRL1506
(Lr06) were obtained from the CERELA culture collection
(Chacabuco 145, San Miguel de Tucumán, Argentina). Both
strains were selected because their previously reported im-
munomodulatory capacities [6,12]. The culture was kept
freeze-dried and then rehydrated using the following
medium: peptone 15.0 g, tryptone 10.0 g, meat extract
5.0 g, distilled water 1 l, pH 7. It was cultured for 12 h at
37°C (final log phase) in Man-Rogosa-Sharpe broth (MRS,
Oxoid). The bacteria were harvested by centrifugation
at 3000 g for 10 min, washed three times with sterile
0.01 mol/l phosphate buffer saline (PBS), pH 7.2, and
resuspended in sterile 10% non-fat milk. Non-viable
Lr05 and Lr06, designated as HkLr05 and HkLr06 re-
spectively, were obtained as follows: bacteria were killed
by tyndallization in a water bath at 80°C for 30 min and
the lack of bacterial growth was confirmed using MRS
agar plates [11].
Animals and feeding procedures
Female 3-week-old BALB/c mice were obtained from the
closed colony kept at Tohoku University. They were
housed in plastic cages at room temperature. Mice were
housed individually during the experiments and the assays
for each parameter studied were performed in 5–6 mice
per group for each time point. Lr05, Lr06, HkLr05 or
HkLr06 were nasally administered to different groups of
mice for 2 consecutive days at a dose of 108 cells/mouse/
day in 50 μl of PBS. The treated groups and the untreated
control group were fed a conventional balanced diet ad
libitum. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Guidelines for Animal
Experimentation of Tohoku University, Sendai, Japan. The
present study was approved by the Institution Animal
Care and Use Committee of Tohoku University and all
efforts were made to minimize suffering [5-8].
Intranasal administration of poly(I:C)
Administration of the viral pathogen molecular pattern
poly(I:C) was performed on day 3, after the two days treat-
ments with lactobacilli, as described previously [12]. Mice
were lightly anesthetized and 100 μl of PBS, containing
250 μg poly(I:C) (equivalent to 10 mg/kg body weight), was
administered dropwise, via the nares. Control animals re-
ceived 100 μl of PBS. Mice received three doses of poly(I:C)
or PBS with 24 hs rest period between each administration.
Cytokine concentrations in serum and broncho-alveolar
lavages (BAL)
Blood samples were obtained through cardiac puncture at
the end of each treatment and collected in heparinized
tubes. BAL samples were obtained as described previously
[8]. Briefly, the trachea was exposed and intubated with a
catheter, and 2 sequential bronchoalveolar lavages were
performed in each mouse by injecting sterile PBS; the re-
covered fluid was centrifuged for 10 min at 900 × g; the
pellet was used to make smears that were stained for cell
counts; and the fluid was frozen at −70°C for subsequent
cytokines analyses. Tumour necrosis factor (TNF)-α,
IFN-α, IFN-β, IFN-γ, IL-6 and IL-10 concentrations in
serum and BAL were measured with commercially
available enzyme-linked immunosorbent assay (ELISA)
technique kits following the manufacturer's recommen-
dations (R&D Systems, MN, USA) [6].
Lung injury parameters
Protein and albumin content, a measure to quantitate in-
creased permeability of the bronchoalveolar–capillarity
barrier, and lactate dehydrogenase (LDH) activity, an indi-
cator of general cytotoxicity, were determined in the acel-
lular BAL fluid [8]. Protein content was measured by the
bicinchoninic acid assay (BCA) protein assay (Pierce Bio-
technology Inc., Rockford, IL). Albumin content was de-
termined colorimetrically based on albumin binding to
bromcresol green using an albumin diagnostic kit (Wiener
Lab, Buenos Aires, Argentina). LDH activity, expressed as
units per liter of BAL fluid, was determined by measuring
the formation of the reduced form of nicotinamide aden-
ine dinucleotide (NAD) using the Wiener reagents and
procedures (Wiener Lab). Lung wet:dry weight ratio was
measured as previously described [12]. Wet:dry weight ra-
tio was calculated as an index of intrapulmonary fluid ac-
cumulation, without correction for blood content.
Lung cells preparation
Single lung cells from mice were prepared using the pre-
viously described method [12]. Mice were anaesthetized
with diethyl ether and killed the next day by exsanguin-
ation. Lungs were removed, finely minced and incubated
for 90 min with 300 U of collagenase (Yakult Honsha
Co., Tokyo, Japan) in 15 ml of RPMI 1640 medium
(Sigma, Tokyo, Japan). To dissociate the tissue into sin-
gle cells, collagenase-treated minced lungs were gently
tapped into a plastic dish. After removal of debris, eryth-
rocytes were depleted by hypotonic lysis. The cells were
washed with RPMI medium supplemented with 100 U/ml
of penicillin and 100 mg/ml of streptomycin and then
resuspended in a medium supplemented with 10% heat-
inactivated foetal calf serum (FCS). Cells were counted
using Trypan Blue exclusion and then resuspended at an
appropriate concentration of 5 × 106 cells/ml.
Flow cytometry studies
Lung cell suspensions were pre-incubated with anti-
mouse CD32/CD16 monoclonal antibody (Fc block) for
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15 min at 4°C. Cells were incubated in the antibody
mixes for 30 min at 4°C and washed with FACS buffer.
The following antibodies from BD PharMingen were
used: anti-mouse CD3-FITC, anti-mouse CD4-PE, anti-
mouse CD8-PE, anti-mouse IFN-γ-APC, anti-mouse
CD11b-FITC, anti-mouse CD11c-PE, anti-mouse IFN-γ
-PE, anti-mouse MHC-II-PE, anti-mouse IL-10-PE and
anti-mouse CD103-biotin. Following incubation with
biotinylated primary antibodies, the labeling was re-
vealed using streptavidin-PercP. In all cases, cells were
then acquired on a BD FACSCalibur™ flow cytometer
(BD Biosciences) and data were analyzed with FlowJo
software (TreeStar). The total number of cells in each
population was determined by multiplying the percent-
ages of subsets within a series of marker negative or
positive gates by the total cell number determined for
each tissue [12,17].
Virus and infection
Human RSV strain A2 was grown in Vero cells as de-
scribed by Murawski et al. [18]. Briefly, Vero cells were
infected with RSV at a multiplicity of infection (MOI) of
1 in 5 ml of Dulbecco’s modified Eagle’s medium
(DMEM). Cells were infected for 2.5 h at 37°C and 5%
CO2. After infection, 7 ml of DMEM with 10% fetal
bovine serum (Sigma, Tokyo, Japan), 0.1% penicillin-
streptomycin (Pen/Strep) (Sigma, Tokyo, Japan), and
0.001% ciprofloxacin (Bayer) was added to the flask.
Flasks were incubated until extensive syncytium forma-
tion was observed. Then, cells were scraped from the
flask and sonicated three times, 5 s per time, at 25 W on
ice. Cell debris was removed by centrifugation at 700 g
for 10 min at 4°C. Virus supernatant was sucrose density
gradient purified and stored in 30% sucrose at −80°C.
Uninfected flasks were treated identically to generate
Vero cell lysate control. For in vivo infection, mice were
lightly anesthetized with isoflurane and intranasally chal-
lenged with 2.4 × 106 PFU of RSV strain A2.
RSV immunoplaque assay
Lung tissue was removed without BAL harvest and stored
in 30% sucrose for plaque assay. Lungs were homogenized
using a pellet pestle and centrifuged at 2,600 × g for 10
min at 4°C to clarify supernatant. Twenty-four-well tissue
culture plates were seeded with 1.5 × 105 Vero cells/well
in DMEM containing 10% FBS, 0.1% Pen/Strep, and
0.001% ciprofloxacin. Cells were incubated overnight at
37°C and 5% CO2. Medium was removed from confluent
monolayers, and serial dilutions of lung tissue-clarified su-
pernatants were absorbed to monolayers. All samples were
run in triplicate wells. Plates were incubated at 37°C and
5% CO2 for 2.5 h for optimum infection. After incubation,
supernatant was removed, and 1 ml of fresh DMEM
medium containing containing 10% FBS, 0.1% Pen/Strep,
and 0.001% ciprofloxacin was overlaid on monolayers.
When extensive syncytia developed, the overlay was re-
moved and monolayers were fixed with 1 ml of ice-cold
acetone:methanol (60:40). Primary RSV anti-F (clones
131-2A; Chemicon) and anti-G (Mouse monoclonal [8C5
(9B6)] to RSV glycoprotein, Abcam) antibodies were
added to wells for 2 h, followed by secondary horseradish
peroxidase anti-mouse immunoglobulin antibody (Anti-
mouse IgG, HRP-linked Antibody #7076, Cell signaling
Tehcnology) for 1 h. Plates washed twice with PBS
containing 0.5% Tween 20 (Sigma) after each antibody in-
cubation step. Individual plaques were developed using a
DAB substrate kit (ab64238, Abcam) following manufac-
ture’s specifications. Results for immunoplaque assay were
expressed as log10 PFU/g of lung.
Statistical analysis
Experiments were performed in triplicate and results were
expressed as mean ± standard deviation (SD). After verifi-
cation of the normal distribution of data, 2-way ANOVA
was used. Tukey's test (for pairwise comparisons of the
means) was used to test for differences between the
groups. Differences were considered significant at p<0.05.
Results
Nasally administered L. rhamnosus CRL1505 and L.
rhamnosus CRL1506 differentially modulate respiratory
immunity
In order to evaluate the changes induced by nasally admin-
istered LAB in the respiratory immune system we deter-
mined the levels of different cytokines in BAL (Figure 1A).
The four nasal treatments used in this study Lr05, HkLr05,
Lr06 and HkLr06 increased the levels of IL-6, IFN-α and
IFN-β in BAL, however concentrations of these cytokines
were significantly higher in Lr06- and HkLr06-treated mice
than in mice receiving Lr05 or HkLr05 (Figure 1A). All the
treatments were also able to increase BAL IFN-γ, being
both viable and heat-killed L. rhamnosus CRL1505 more
efficient to improve the levels of this cytokine than L.
rhamnosus CRL1506 (Figure 1A). BAL TNF-α and IL-10
concentrations were increased by the immunobiotic nasal
treatments. We observed that viable cells were more effi-
cient to upregulate TNF-α than heat-killed strains while no
differences were found in IL-10 levels when comparing vi-
able and heat-killed lactobacilli (Figure 1A). When we eval-
uated the levels of IL-6, IFN-α, IFN-β, IFN-γ, TNF-α and
IL-10 in serum we found that lactobacilli treatments in-
duced similar changes than those observed in the respira-
tory tract (Figure 1B). IL-6, IFN-α and IFN-β were more
efficiently increased with L. rhamnosus CRL1506 treat-
ments while the highest levels of serum IFN-γ were ob-
served in Lr05 and HkLr05 groups (Figure 1B). Serum
TNF-α and IL-10 concentrations were also enhanced by
the immunobiotic nasal treatments, being viable and heat-
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killed lactobacilli equally effective to improve both cyto-
kines whit the exception of HkLr06 that induced signifi-
cantly lower levels of IL-10 when compared with the other
treatments (Figure 1B).
We also evaluated the changes induced by nasally ad-
ministered lactobacilli in lung immune cells using flow
cytometry. Slightly increases of lung CD3+CD4+ T cells
were observed in lactobacilli-treated mice, however
when we studied the cells able to produce IFN-γ within
this population, mice receiving Lr05, HkLr05 and Lr06
showed significant differences when compared to control
mice (Figure 2). Nasally administered Lr05 and HkLr05
A 
B 
Figure 1 Effect of lactobacilli on systemic and respiratory immunity. Effect of viable (Lr05) or heat-killed (HkLr05) Lactobacillus rhamnosus
CRL1505 and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus CRL1506 nasal administration on the tumor necrosis factor (TNF)-α, interferon (IFN)-α,
IFN-β, IFN-γ, interleukin (IL)-6, and IL-10 concentrations in broncho-alveolar lavages (A) and serum (B). Lr05, Lr06, HkLr05 or HkLr06 were nasally
administered to different groups of mice for 2 consecutive days at a dose of 108 cells/mouse/day and the levels of BAL and serum cytokines
were studied on day 3. The results represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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increased the number of CD3+CD4+IFN-γ+ T cells in
lungs being Lr05 more efficient than HkLr05 to increase
this cell population (Figure 2). Only Lr05 enhanced the
number of CD3+CD4+IL-10+ T cells in lungs (Figure 2). No
modifications were observed in the number of CD3+CD8+
and CD3+CD8+IFN-γ+ T cells in lactobacilli-treated
mice (Figure 2).
Two populations of myeloid DCs can be defined in lungs
using CD11c, CD11b, CD103 and MHC-II antibodies as
described previously [12,19]: MHC-II+CD11c+CD11blow
CD103+ and MHC-II+CD11c+CD11bhighCD103- cells.
Therefore, we next aimed to evaluate the effect of nasally
administered lactobacilli on these populations of DCs from
lungs. Lr05 and HkLr05 significantly increased the number
of both lung CD11c+CD11blowCD103+ and CD11c
+CD11bhighCD103- DCs. In addition, Lr06 and HkLr06 en-
hanced the number of lung CD11c+CD11blowCD103+ DCs
while no quantitative changes were detected in CD11c
+CD11bhighCD103- DCs populations in lungs of Lr06- and
HkLr06-treated mice (Figure 2). In addition, the expression
of MHC-II in both DCs population was significantly im-
proved with all the treatments, however L. rhamnosus
CRL1505 was more efficient than L. rhamnosus CRL1506
to upregulate the expression of MHC-II in lung DCs
(Figure 2).
Poly(I:C)-induced lung injuries are reduced by nasally
administered lactobacilli
We next aimed to evaluate the effect of nasally adminis-
tered lactobacilli on the immune response triggered by
nasal administration of the viral pathogen-associated
molecular pattern poly(I:C). Our previous work demon-
strated that the nasal challenge of mice with poly(I:C)
significantly alters lungs function and induce lung injuries
[12]. In this experimental model an altered wet:dry weight
ratio can be observed after poly(I:C) challenge (Figure 3).
Moreover, significantly increased levels of LDH activity as
well as protein and albumin concentrations can be found
Figure 2 Effect of lactobacilli on respiratory immune cells populations. Effect of viable (Lr05) or heat-killed (HkLr05) Lactobacillus rhamnosus
CRL1505 and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus CRL1506 nasal administration on CD3+CD8+IFN-γ+, CD3+CD4+IFN-γ+ and
CD3+CD4+IL-10+ T cells and CD11c+CD11blowCD103+ and CD11c+CD11bhighCD103- dendritic cells from lung. Lr05, Lr06, HkLr05 or HkLr06
were nasally administered to different groups of mice for 2 consecutive days at a dose of 108 cells/mouse/day and lung immune cells were studied on
day 3. The results represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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in BAL samples of challenged mice indicating that poly(I:C)
produces local cellular damage and impairment of the
alveolar-capillary barrier (Figure 3). We observed that nas-
ally administered lactobacilli prior to poly(I:C) challenge
significantly reduced wet:dry weight ratio and BAL LDH
(Figure 3). In addition, all the treatments were able to sig-
nificantly reduce BAL protein and albumin concentrations
however L. rhamnosus CRL1505 was more efficient than
the CRL1506 strain to reduce the impairment of the
alveolar-capillary barrier (Figure 3).
Nasally administered lactobacilli beneficially modulate
immune response triggered by poly(I:C) challenge
The pulmonary immune response induced by the nasal
challenge with poly(I:C) and the effect of nasally admin-
istered lactobacilli in that response were next evaluated.
We have previously study the levels and kinetics of IFN-
α, IFN-β, IFN-γ, IL-6, IL-4, TNF-α, IL-1β, IL-8, MCP-1,
IL-10 and TGF-β in BAL after poly(I:C) challenge and
the effect of orally administered immunobiotics in that
response [12]. The most significant changes induced by
oral treatment with immunobiotics were found in the
levels of IFN-α, IFN-β, IFN-γ, IL-6, TNF-α and IL-10,
therefore these cytokines were studied in this work.
Nasal administration of poly(I:C) significantly increased
respiratory levels of the pro-inflammatory mediators
IFN-α, IFN-β, IL-6 and TNF-α (Figure 4) as previously
reported [12]. All lactobacilli treatments significantly in-
creased the levels of BAL IFN-α, IFN-β and TNF-α how-
ever, Lr06 and HkLr06 were more efficient to enhance
the concentration of these cytokines than Lr05 or
HkLr05 (Figure 4). In addition, IL-6 was not modified in
Lr06 and HkLr06 groups while the levels of this cytokine
were lower in L. rhamnosus CRL1505-treated mice when
compared to controls (Figure 4). Poly(I:C) challenge also
induced an increase in the respiratory levels of IL-10
and IFN-γ and the levels of both cytokines were signifi-
cantly higher in lactobacilli-treated mice, being Lr05 and
HkLr05 more efficient than Lr06 and HkLr06 to achieve
that effects (Figure 4). The nasal challenge with poly(I:C)
also increased cytokines levels in serum as previously
reported [12]. Moreover, the effect of Lr05, HkLr05,
Lr06 and HkLr06 treatments on the production of
serum IFN-α, IFN-β, IFN-γ, IL-6, TNF-α and IL-10 was
similar to that found in BAL (data not shown).
We also studied the changes in lung immune cells in-
duced by nasally administered lactobacilli in poly(I:C)-
challenged mice (Figure 5). Poly(I:C) administration
increased CD3+CD8+IFN-γ+ and CD3+CD4+IFN-γ+ T
cells as we described previously [12]. In addition, in this
work we also observed an increase in CD3+CD4+IL-10+ T
cells after the challenge with poly(I:C) (Figure 5). Our
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Figure 3 Effect of lactobacilli on lung injuries induced by the nasal administration of the viral pathogen-associated molecular pattern
poly(I:C). Effect of viable (Lr05) or heat-killed (HkLr05) Lactobacillus rhamnosus CRL1505 and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus
CRL1506 nasal administration on lung wet:dry weight ratio, lactate dehydrogenase (LDH) activity and, albumin and protein concentrations in
broncho-alveolar lavages (BAL) after the challenge with poly(I:C). Lr05, Lr06, HkLr05 or HkLr06 were nasally administered to different groups of
mice for 2 consecutive days at a dose of 108 cells/mouse/day. After lactobacilli treatment, mice received three doses of poly(I:C) with 24 hours
rest period between each administration. Lung tissue injury markers were studied 24 hours after the third challenge with poly(I:C). The results
represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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results showed that nasally administered lactobacilli were
able to increase both CD3+CD4+IFN-γ+ and CD3+CD4+IL-
10+ T cells in lungs, however the levels of these cell popu-
lations in Lr05- and HkLr05-treated mice were significantly
higher than those observed in Lr06 and HkLr06 groups
(Figure 5). No differences were observed between
lactobacilli-treated mice and controls when evaluating
CD3+CD8+IFN-γ+ T cells (Figure 5). Poly(I:C) challenge
also increased the number of pulmonary CD11bhighCD103-
MHC-II+ and CD11blowCD103+MHC-II+ DCs when
compared to basal levels in all the experimental groups
(Figure 5). Nasal administration of both L. rhamnosus
CRL1505 and L. rhamnosus CRL1506 significantly in-
creased the numbers of CD11blowCD103+MHC-II+ DCs
cells in lungs when compared to controls while only Lr05-
and HkLr05-treated mice showed improved levels of pul-
monary CD11bhighCD103-MHC-II+ DCs (Figure 5).
Nasally administered lactobacilli improve resistance
against respiratory syncytial virus infection
We next addressed the question of whether changes ob-
served in respiratory immune system caused by the
intervention with immunobiotics affected the outcome
of RSV infection in mice. Therefore, infant mice were
nasally treated with Lr05, HkLr05, Lr06 or HkLr06 and
then challenged with 106 PFU of RSV. Viral loads in
lungs of infected mice were followed for five days after
the challenge (Figure 6). RSV was detected in lungs of
all the experimental groups during the five days post-
infection and all groups showed a peak of virus counts
on day 4 after the challenge. However, lactobacilli-
treated mice showed significantly lower lung viral loads
when compared to control mice. Lr05 and HkLr05 treat-
ments were equally effective to reduce RSV replication
in lungs while in the case of L. rhamnonus CRL1506 vi-
able bacteria was more effective than heat-killed cells to
improve protection against the respiratory viral infection
(Figure 6). In addition, we observed significantly differ-
ences in the body weight of infected mice when compar-
ing lactobacilli-treated mice and controls (Figure 6).
Lr05, HkLr05 and Lr06 significantly improved the body
weight during RSV infection while HkLr06-tretated mice
showed no differences when compared to controls
(Figure 6). We also evaluated the markers of lung tissue
damage in RSV-infected mice. As showed in Figure 7,
challenge with RSV significantly increase lung wet:dry
weight, BAL protein concentrations and LDH activity.
All these markers of lung tissue damage were significantly
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Figure 4 Effect of lactobacilli on the production of cytokines induced by the nasal administration of the viral pathogen-associated
molecular pattern poly(I:C). Effect of viable (Lr05) or heat-killed (HkLr05) Lactobacillus rhamnosus CRL1505 and viable (Lr06) or heat-killed
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IL-10 concentrations in broncho-alveolar lavages (BAL). Lr05, Lr06, HkLr05 or HkLr06 were nasally administered to different groups of mice for 2
consecutive days at a dose of 108 cells/mouse/day. After lactobacilli treatment, mice received three doses of poly(I:C) with 24 hours rest period
between each administration. BAL cytokines were studied 12 (TNF-α, IFN-α, IFN-β and IL-6) or 48 (IFN-γ and IL-10) hours after the third challenge
with poly(I:C). The results represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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higher in RSV-challenged control mice than in those pre-
viously treated with Lr05, HkLr05 or Lr06 (Figure 7). On
the contrary, lung wet:dry weight, BAL protein concentra-
tions and BAL LDH activity in HkLr06-treated mice were
not different from controls (Figure 7).
Nasally administered lactobacilli differentially modulate
the cytokines response to respiratory syncytial virus
infection
Finally, we addressed whether the improvement in the
resistance against RSV induced by lactobacilli treatments
was related to a differential modulation of cytokines pro-
duction during infection (Figure 8). Therefore, we evalu-
ate the levels of BAL and serum IL-6, IFN-β and TNF-α
on day 2 post-infection and the concentrations of IFN-γ
and IL-10 on day 5 after challenge. We observed that
the challenge with RSV significantly increased the levels
of the cytokines studied in all experimental groups. We
also detected that lactobacilli-treated mice showed sig-
nificantly higher levels of BAL IL-6, IFN-β and TNF-α
than controls, being Lr06 and HkLr06 treatments more
efficient than Lr05 or HkLr05 to improve the production
of these factors (Figure 8). In addition, levels of IFN-γ
and IL-10 were significantly improved by Lr05, HkLr05
and Lr06 treatments while nasal administration of
HkLr06 increased IFN-γ but not IL-10 production in the
respiratory tract. Moreover, Lr05 and HkLr05 were more
effective than Lr06 to increase BAL IFN-γ and IL-10
concentrations in response to RSV challenge (Figure 8).
The effect of Lr05, HkLr05, Lr06 and HkLr06 treatments
on the production of serum TNF-α, IFN-β, IL-6, IFN-γ
and IL-10 was similar to that found in BAL (data not
shown).
Discussion
In the present work we studied the effect of nasally ad-
ministered immunobiotic lactobacilli on the respiratory
antiviral immune response and evaluated their capacity
to improve protection of infant mice against RSV infec-
tion. Three important conclusions can be inferred from
the results presented in this study: a) nasally adminis-
tered Lr05 and Lr06 differentially modulate the TLR3/
RIG-I-triggered antiviral respiratory immune response;
b) nasal priming with Lr05 or Lr06 strains increase the
resistance of infant mice to RSV infection and; c) the
viability of the immunobiotic strains is not a necessary
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Figure 6 Effect of lactobacilli on the resistance against respiratory syncytial virus (RSV) infection. Effect of viable (Lr05) or heat-killed
(HkLr05) Lactobacillus rhamnosus CRL1505 (A) and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus CRL1506 (B) nasal administration on the
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Figure 7 Effect of lactobacilli on lung injuries induced by respiratory syncytial virus (RSV) infection. Effect of viable (Lr05) or heat-killed
(HkLr05) Lactobacillus rhamnosus CRL1505 (A) and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus CRL1506 (B) nasal administration on lung
tissue injuries induced by RSV infection. Lr05, Lr06, HkLr05 or HkLr06 were nasally administered to different groups of mice for 2 consecutive days
at a dose of 108 cells/mouse/day. After lactobacilli treatment, mice were nasally challenged with RSV and wet:dry weight ratio, lactate
dehydrogenase (LDH) activity and, albumin and protein concentrations in broncho-alveolar lavages (BAL) were studied in different time points
after the challenge. The results represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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condition to achieve the immunoregulatory protective
effect.
a) Nasally administered Lr05 and Lr06 differentially
modulate the TLR3/RIG-I-triggered antiviral respiratory
immune response. We have previously demonstrated that
nasal administration of three once-daily doses of poly(I:C)
resulted in a marked impairment of lung function that
was accompanied by inflammatory cell recruitment into
the airways and the production of pro-inflammatory medi-
ators [12]. Accordingly, in the present work we observed
increased LDH activity and albumin concentration in BAL
as well as increased levels of type I IFNs, TNF-α and IL-6,
in the respiratory tract of poly(I:C)-challenged mice. We
also showed that this immune response can be modulated
with the preventive nasal administration of Lr05 or Lr06,
demonstrating in addition that each strain has a different
immunoregulatory effect. While Lr06 administration had
a significant effect on the production of IFN-α, IFN-β and
IL-6 in the response to poly(I:C) challenge, nasal priming
with Lr05 was more effective to improve levels of IFN-γ
and IL-10.
It was demonstrated that poly(I:C) elicited the secretion
of type I IFNs, TNF-α and IL-6 and other cytokines in re-
spiratory epithelial cells [20], therefore a likely source of
these cytokines following poly(I:C) administration may be
the airway epithelium. Then, Lr06 administration would
have a significant effect on respiratory epithelial cells. Tak-
ing into consideration that IFN-α and IFN-β up-regulate
several genes involved in viral defense but also genes of
major importance for the development of a strong Th1
response, it can be speculated that Lr06 may play
an important role in the improvement of innate and
specific immune responses against respiratory virus
through the stimulation of antiviral defenses in epithe-
lial cells (Figure 9). In addition, we have previously
demonstrated that nasal administration of poly(I:C) ac-
tivates respiratory MHC-II+CD11c+CD11blowCD103+
(CD103+ DCs) and MHC-II+CD11c+CD11bhighCD103-
(CD11bhigh DCs) cells and increases CD3+CD4+IFN-γ+
and CD3+CD4+IFN-γ+ T cells in lungs, indicating the
generation of a Th1 response [12]. The result presented
here shows that nasal administration of Lr05 has the
capacity to improve Th1 response since higher levels of
BAL IFN-γ and lung CD3+CD4+IFN-γ+ T cells were
found in Lr05-treated mice. Moreover, we showed that
Lr05 administration significantly activated CD103+ DCs,
an affect that was not achieved by Lr06. Considering
that recent studies suggested that lung CD103+ DCs are
more potent at eliciting Th1 and Th17 responses than
CD11bhigh DCs [21], we can speculate that Lr05 is more
efficient than Lr06 to stimulate CD103+ DCs and improve
Th1 response in the respiratory tract (Figure 9).
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Figure 8 Effect of lactobacilli on the production of cytokines induced by respiratory syncytial virus (RSV) infection. Effect of viable (Lr05)
or heat-killed (HkLr05) Lactobacillus rhamnosus CRL1505 and viable (Lr06) or heat-killed (HkLr06) L. rhamnosus CRL1506 nasal administration on
the tumor necrosis factor (TNF)-α, interferon (IFN)-α, IFN-β, IFN-γ, interleukin (IL)-6 and IL-10 concentrations in broncho-alveolar lavages (BAL).
Lr05, Lr06, HkLr05 or HkLr06 were nasally administered to different groups of mice for 2 consecutive days at a dose of 108 cells/mouse/day. After
lactobacilli treatment, mice were nasally challenged with RSV and BAL cytokines were studied 12 (TNF-α, IFN-β and IL-6) or 48 (IFN-γ and IL-10)
hours after the challenge. The results represent data from three independent experiments. Different letters indicate significant differences (P < 0.05).
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Nasal treatment with lactobacilli significantly reduced
lung injuries caused by poly(I:C) administration. We
previously suggested that IL-10 would be valuable for at-
tenuating inflammatory damage and pathophysiological
alterations in lungs challenged with the viral pathogen-
associated molecular pattern poly(:IC) [12]. We dem-
onstrated here that both Lr05 and Lr06 significantly
improved the production of IL-10 in response to poly(:IC),
however Lr05 was more efficient than Lr06 to upregulate
the levels of this cytokine in the respiratory tract. More-
over, the lung tissue injury markers used in this study
were significantly lower in Lr05-treated mice than in
those receiving the Lr06 strain. Therefore, we con-
firmed that there is a direct connection between the im-
provement of IL-10 levels induced by immunobiotics
and the protection against lung injury after respiratory
poly(I:C) challenge. Moreover, in this work we demon-
strated that CD3+CD4+IL-10+ T cells would be the
source of the IL-10 produced after poly(I:C) challenge
and that this immune cell population would be quanti-
tatively and functionally modulated by Lr05 since in-
creased levels of CD3+CD4+IL-10+ T cells were found in
lungs of Lr05-treated mice when compared with con-
trols and those receiving Lr06 (Figure 9). Recently,
Figure 9 Proposed mechanism for the improvement of antiviral immunity and resistance against respiratory syncytial virus (RSV)
infection induced by nasally administered lactobacilli.
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Weiss et al. [4] demonstrated that CD4+ T cells produce
the majority of IL-10 in vivo during an acute RSV infec-
tion and that this cell population is involved in the pro-
tective effect against lung tissue damage. Therefore, the
increase in the numbers of CD4+IL-10+ T cells induced
by nasal treatment with lactobacilli could have an im-
portant role in the protection against RSV infection.
Similar to the changes observed in intestinal immunity
after oral administration of Lr05 or Lr06 [12], we dem-
onstrated in this work that nasal priming with both
lactobacilli has the ability to improve antiviral immunity
but using different mechanisms (Figure 9). Moreover,
considering that activating host immune responses dur-
ing RSV infection is dependent on complex signaling
events initiated in part by PRRs such as TLR3 or RIG-I
and that these coordinated signaling events promote the
production of cytokines, chemokines, IFN-α, IFN-β and
IFN-γ in the lung that are crucial for the virus clearance,
we speculated that Lr05 or Lr06 nasal treatments would
beneficially modulate the immune response against RSV
and improve resistance of mice against this viral respira-
tory infection.
b) Nasal priming with Lr05 or Lr06 strains increase re-
sistance of infant mice to RSV challenge. In the last years,
some lines of evidence showed that nasal administration
of immunobiotics is able to increase resistance against
respiratory viral infections [22]. It was reported that in-
tranasal priming with L. rhamnosus GG to BALB⁄c mice
significantly reduced the frequency of accumulated symp-
toms and induced a higher survival rate than control mice
after challenge with influenza virus H1N1 [23]. Authors
demonstrated that L. rhamnosus GG significantly in-
creased lung NK cell activation and expression of TNF-α,
IL-1β and MCP-1 enhancing respiratory cell-mediated im-
mune responses. In addition, it was reported recently that
nasal priming with lactobacilli is highly effective at sup-
pressing virus-induced inflammation in a pneumonia virus
mouse model [16]. Nasal priming with lactobacilli resulted
in marked suppression of IFN-inducible protein-10
(CXCL10), MCP-1 (CCL2), neutrophil-activating protein-
3 (CXCL1), MIP-1γ (CCL9), TNF, and eotaxin-2 (CCL24)
in response to pneumovirus infection and significantly in-
creased the resistance against the lethal disease. In this
work we extend these findings by demonstrating that nas-
ally administered immunobiotics are able to increase pro-
tection against RSV infection in infant mice.
We observed that challenge of three weeks old BALB/c
mice with RSV significantly altered lung function, induced
tissue injury and triggered inflammatory response. This is
in line with previous work reporting that RSV intranasal
infection led to significant clinical characteristics in female
BALB/c mice [24]. Authors described ruffled fur and
ataxia that occurred early after hour 12 post-RSV infec-
tion and continued for 3 days [24]. Natural human RSV
infection in children and experimental RSV inoculation
in mice result in prominent local secretion of pro-
inflammatory cytokines, such as TNF-α, IL-6, IL-8,
MIP-1, RANTES, and MCP-1 as well as type I IFNs
[25]. It has been shown that type I IFNs, IL-6 and TNF-
α contribute to clearance of the virus during the early
stages of RSV infection however, continued production
of these pro-inflammatory mediators exacerbates illness
and tissue injuries during the late stages of RSV infec-
tion [26]. Interestingly, it was found that IL-10 defi-
ciency during RSV challenge did not affect viral load,
but led to markedly increased disease severity with
enhanced weight loss, delayed recovery and a greater
influx of inflammatory cells into the lung and airways
and enhanced release of inflammatory mediators [27].
Therefore, during acute RSV infection, it is imperative
that the host’s inflammatory response is tightly regu-
lated, enabling virus elimination but limiting the detri-
mental effects of inflammation on the lung tissue. Then,
an adequate balance of pro-inflammatory and anti-
inflammatory factors is essential for a safe and effective
antiviral immune response [28]. Moreover, considering
that it was reported that no changes in peak viral titers
or viral clearance were observed between IL-10 KO or
anti–IL-10R mAb-treated mice compared with their
controls [4], preventive or therapeutic approaches aimed
at increasing IL-10 production may offer a means to de-
crease RSV-induced immunopathology without affecting
viral clearance.
We demonstrated in this work that nasal administra-
tion of Lr05 or Lr06 improved the production of pro-
inflammatory mediators in response to RSV challenge
and also the production of IL-10, which would allow an
effective immunological clearance of the virus without
affecting lung tissue. Similarly to our results using poly
(I:C) challenge, we observed that Lr05 was the strain
with the highest capacity to improve levels of IL-10 and
was more effective than Lr06 to enhance virus clearance
and to protect lungs against the inflammatory damage.
Then, our results also support the idea that modulation
of respiratory IL-10 during RSV infection is an effect-
ive way to improve the outcome of viral disease. More-
over, we demonstrated here that nasally administered
immunobiotics are an interesting alternative to achieve
that immunoprotective effect.
Following RSV infection, there is an initial influx of
NK cells to the site of infection that produce IFN-γ and
are cytotoxic to virus-infected cells. This is followed by
recruitment of helper CD4+ and cytotoxic CD8+ lym-
phocytes to the site of infection. IFN-γ enhances the
differentiation of CD8+ lymphocytes and influences the
differentiation of CD4+ lymphocytes that contribute to
the generation and amplification of the humoral and cel-
lular immune responses. While the RSV-specific T cell
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response plays a major role in viral clearance and the clini-
cal outcome of infection, both Th2-biased CD4+ and CD8+
T cells have been implicated in immunopathogenesis [29].
In general, a Th2 immune response is favored during RSV
infection, especially in younger hosts. RSV-induced pul-
monary inflammation in mice was previously found to
cause a shift from Th1 to Th2 cell inflammation. RSV uses
multiple mechanisms to induce a Th2 cell response in
the host, including RSV G protein–mediated effects [30],
increasing IL-4 production from basophils [31] and induc-
tion of alternatively activated macrophages [32]. Moreover,
the excessive mucus production, airway plugging, whee-
zing, and long-lasting effects on lung function that are
common manifestations of RSV disease have some simi-
larity with asthma, which involves a Th2-bias [29]. There-
fore, strategies aimed to improve Th1 during RSV
infection would beneficially modulate the outcome of
the infections especially in younger hosts. In this work,
we showed that nasally administered immunobiotics
were able to improve respiratory Th1 response since
significantly higher levels of IFN-γ were found in the
respiratory tract of lactobacilli-treated mice. Then,
modulation of respiratory immunity potentiated by the
immunobiotic strains might contribute to an improved
Th1 response and thereby favor protective immunity
against viral infections such as RSV.
c) Viability of the immunobiotics strains is not a neces-
sary condition to achieve the immunoregulatory protect-
ive effect. Few studies have demonstrated that the nasal
administration of heat-killed immunobiotics is able to im-
prove resistance against respiratory pathogens [11,15,16].
In this regard, earlier studies by Hori et al. [15] showed
that the nasal administration of heat-killed L. casei Shirota
stimulated cellular immunity in the respiratory tract and
significantly increased the resistance of adult BALB/c mice
to influenza virus infection. The authors investigated the
production of various cytokines by mediastinal lymphoid
node cells in mice receiving L. casei Shirota intranasally
and found that the Shirota strain strongly induced produc-
tion of IL-12 in these cells, which is an important cytokine
for cytotoxic T cells and NK cells stimulation and en-
hancement of Th1 cytokines. In addition, both IFN-γ and
TNF-α levels were improved in mediastinal lymphoid
node cell cultures from mice administered L. casei Shirota
intranasally, after influenza virus challenge [15]. Later it
was reported that intranasal administration of heat-killed
L. pentosus S-PT84 strongly enhanced Th1 immunity,
IFN-α production and NK activity in the respiratory
immune system and protected against influenza virus in-
fection [33]. In addition, as mentioned above, it was dem-
onstrated that priming of the respiratory mucosa with
lactobacilli results in full protection from the otherwise le-
thal severe pneumovirus infection and that protection is
observed in response to both live and heat-killed L.
plantarum and L. reuteri [16]. That work demonstrated
that nasal treatment with heat-killed immunobiotics
resulted in diminished virus recovery at multiple time
points and prominent suppression in the production of
virus-induced proinflammatory mediators. The results of
our work are in line with these previous observations since
administration of both Lr05 and HkLr05 were equally ef-
fective to improve resistance of infant mice to RSV infec-
tion and reduce lung injuries. Interestingly, although both
Lr06 and HkLr06 showed a similar capacity to reduce lung
RSV titers, Lr06 was more effective than HkLr06 to reduce
lung injuries during RSV infection. These differential ef-
fects achieved by the four treatments would be related to
their specific capacities to modulate the production of
IFN-γ and IL-10 after RSV challenge. All of them were
able to improve respiratory IFN-γ levels and reduced viral
loads, while Lr05, Lr06 and HKLr05 but not HkLr06 in-
creased IL-10 and reduced lung injuries. Then our results
suggest that not all the heat-killed bacteria derived from
immunobiotic strains maintain the immunoregulatory ef-
fect after heat treatment. This would be an important
point to consider when selecting immunoactive non-
viable strains.
Previously, we demonstrated that the nasal treatment of
malnourished mice with heat-killed L. casei CRL431 was
able to increase their resistance to the infection with the
respiratory pathogen S. pneumoniae [11]. The results from
that study suggested that heat-killed lactobacilli are also
effective in the immunomodulation of the respiratory im-
mune system in immunocompromised hosts. Therefore,
immunobiotic bacteria in the form of live cells may not be
required for enhancing respiratory defenses against bacter-
ial and viral pathogens. Our previous and present results
show that non-viable immunobiotics or their cellular frac-
tions could be an interesting alternative as mucosal adju-
vants, especially in immunocompromised hosts in which
the use of live bacteria might be dangerous. In addition,
heat-killed immunobiotic have the advantages of allowing
a longer product shelf-life, easier storage, and transporta-
tion. Therefore, to study the capacity of non-viable Lr05
or its cellular fractions to beneficially modulate the im-
mune response against respiratory virus infections in im-
munocompetent and immunocompromised hosts is an
interesting topic for future research.
Conclusions
In the present work we demonstrated that nasal admin-
istration of immunobiotics is able to beneficially modu-
late the immune response triggered by TLR3/RIG-I
activation in the respiratory tract and to increase the re-
sistance of mice to the challenge with RSV. As it has
been reported for orally administered probiotic bacteria,
our results demonstrated that the immunoregulatory
effect of nasally administered lactobacilli is a strain
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dependent effect. Comparative studies using two Lacto-
bacillus rhamnosus strains of the same origin and with
similar technological properties [6,7] showed that each
strain has an specific immunoregulatory effect in the re-
spiratory tract and that they differentially modulate the
immune response after poly(I:C) or RSV challenges, con-
ferring different degree of protection and using distinct
immune mechanisms. We also demonstrated in this
work that is possible to beneficially modulate the re-
spiratory defenses against RSV by using heat-killed
immunobiotics. Moreover, our results showed that not
all heat-killed bacteria derived from viable strains with
immunomodulatory capacity, are also able to func-
tionally modulate the respiratory immune system.
Therefore, detailed studies of the immunoregulatory
capacities of heat-killed immunobiotics or their cellu-
lar fractions are necessary in order to find those with
the highest potential to be used for improving de-
fenses against respiratory viruses.
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